Seaport Therapeutics’ Glyph platform faces its real test as GlyphAllo advances in depression
Seaport Therapeutics’ GlyphAllo data sharpen the case for oral neuroactive steroids in depression. Read what this could change next.
What Seaport Therapeutics’ Glyph platform reveals about the emerging science of gut lymphatic targeting
ARPA-H backs Seaport Therapeutics’ GlyphCele program targeting gut lymphatics in metabolic disease and pancreatic cancer. Read the analysis.